Furthermore, our study also validated partial findings from previous research, such as TBK1 [13], a druggable target identified in our study; however, it was not reported as a prioritized drug target for ALS in other studies [23, 88–90]. Here, TBK1 is linked to amyotrophic lateral sclerosis.